Goldman SachsGSPAST TOP PICKFeb 25, 2021Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
(A Top Pick Jan 28/21, Up 17.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UAL has achieved its $327 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop to $280 (just above our initial recommended entry level). This would all but guarantee a minimum investment return exceeding 9%.